Table 1.
Characteristics of Individuals Within the BC Drug Treatment Program Between 2009 and 2016
| Variable | N = 9358 n (%) |
|---|---|
| ART-treated individualsa | 9358 (100) |
| INSTI-treated individualsb | 3645 (39) |
| INSTI prescribed in the DTPc | |
| Raltegravir | 1546 (17) |
| Elvitegravir | 830 (9) |
| Dolutegravir | 1856 (20) |
| Age, years, median (Q1–Q3)d | 46 (38–53) |
| Sex | |
| Male | 7768 (83) |
| Female | 1590 (17) |
| HIV subtype | |
| B subtype | 7542 (81) |
| Non-B subtype | 586 (6) |
| Unknown | 1230 (13) |
| Number of years individuals contributed resistance data, median (Q1–Q3) | 6 (2–8) |
| Number of years individuals contributed any type of data, median (Q1–Q3) | 7 (4–8) |
| Number of ART-treated individuals ever tested for PI-RT resistance | 7883 (84) |
| Number of physician-ordered resistance tests done per person, median (Q1–Q3) | 2 (1–5) |
| Number of individuals with a single resistance test only, at some point in time | 2647 (28) |
| Number of individuals with a single resistance test performed at baseline | 2109 (23) |
| Number of INSTI-treated individuals ever tested for INSTI resistance | 1244 (13) |
| Number of physician-ordered resistance tests done per person, median (Q1–Q3) | 1 (1–2) |
| Number of individuals with a single resistance test only, at some point in time | 752 (8) |
| Number of individuals with a single resistance test performed at baseline | 482 (5) |
Abbreviations: ART, antiretroviral therapy; BC, British Columbia; DTP, Drug Treatment Program; HIV, human immunodeficiency virus; INSTI, integrase strand transfer inhibitor; Q1–Q3, 25th–75th percentile range.
aAn individual contributed to the count of ART-treated if they were ever dispensed ART in the DTP during the study period.
bAn individual contributed to the count of INSTI-treated if they were ever dispensed INSTIs in the DTP during the study period.
cMedian age of individuals at first year of inclusion in the study.
dAn individual could be prescribed more than 1 INSTI during the study period.